HER2, HER3, and TROP2: Diagnostic Testing and Treatment Implications in Breast, GI, and Lung Cancers

Review the latest expert guidance on assessing and targeting HER2, HER3, and TROP2 in the metastatic setting for diverse malignancies with on-demand Webcasts and downloadable slides from CCO’s live Webinars, along with expert-authored commentaries, a pocket guide on best practices for testing, and brief Medical Minute slide/audio presentations for oncologists and pathologists.
Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD

Downloadable Summary Resource

Download this PDF summarizing key points in HER2, HER3, and TROP2 testing and targeted therapy for patients with breast, GI, and lung cancers.

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Released: July 30, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue